Biotech Fluidics announces DEGASi Prep+, the world’s first in-line membrane degasser ready to use at 150 mL/minute with aggressive media and organic solvents.

AMSBIO announce a new range of high-titer Chimeric Antigen Receptor (CAR) lentivirus that provide high transduction efficiency with long-term, stable expression in resting and actively dividing cells.

Lonza has launched the TheraPEAK® T-VIVO® Cell Culture Medium, a novel chemically defined medium developed to optimize CAR T-cell manufacture.

Autoscribe Informatics has appointed Labtec Egypt Group (LEG) as its distributor for the Matrix Gemini Laboratory Information Management System (LIMS) in Egypt.

Beckman Coulter today unveiled the DxI 9000 Access Immunoassay Analyzer, the most productive immunoassay analyzer per footprint. The DxI 9000 Analyzer can run up to 215 tests per hour per square meter (tests/hr/m2).

Deepcell has announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model and Axon data suite.

Scribe Therapeutics Inc. has announced a strategic collaboration with Prevail Therapeutics, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Personalis, Inc., National Cancer Center and Ono Pharmaceutical Co., Ltd. have announced they have entered into a collaborative agreement to examine the efficacy and safety of nivolumab, an immune checkpoint inhibitor, for resectable rectal cancer with mismatch repair deficiency.

Thermo Fisher Scientific has announced it is making ImmunoCAP™ Specific IgE tests available to more patients across the U.S.

Form Bio has announced the launch of FORMsightAI, a new, AI-based solution set for predicting and optimizing manufacturing outputs of cell and gene therapy constructs.